达卡他韦中间体II

达卡他韦中间体II性质、用途与生产工艺

概述

生产方法 

1009119-82-7

1007882-23-6

以DACLATASVIR INTERMEDIATE-达卡他韦中间体为原料合成(2S,2'S)-二叔丁基2,2'-(4,4'-([1,1'-双苯基]-4,4'-二基)双(1H-咪唑-4,2-二基))双(吡咯烷-1-甲酸酯)的一般步骤：将3（2g，3.01mmol）和NH4OAc（4.65g，60.3mmol）在甲苯（30mL）中的混合物于130℃下加热回流15小时。反应完成后，减压蒸馏除去挥发性组分。将残余物在CH2Cl2和H2O之间进行分配，直至达到饱和。加入饱和NaHCO3水溶液以中和水相。水相用CH2Cl2萃取，合并有机相，用无水MgSO4干燥，过滤，减压浓缩。通过快速柱色谱法（硅胶；50％EtOAc/己烷为洗脱剂）纯化残余物，得到产物4，为白色固体（1.6g，收率85%）。

参考文献：

[1] Bioorganic and Medicinal Chemistry Letters, 2015, vol. 25, # 16, p. 3147 - 3150

[2] Patent: US2009/43107, 2009, A1. Location in patent: Page/Page column 8

[3] Patent: WO2010/138368, 2010, A1. Location in patent: Page/Page column 148-149

[4] Patent: KR101508022, 2015, B1. Location in patent: Paragraph 0136-0138

[5] Patent: CN106496199, 2017, A. Location in patent: Paragraph 0043; 0061; 0070; 0071; 0072

达卡他韦中间体II 上下游产品信息

上游原料

下游产品

达卡他韦中间体II 生产厂家

1007882-23-6, 达卡他韦中间体II 相关搜索:

• API
• 抑制剂
• 化工原料
• 医药原料
• 达卡他韦
• 原料
• C36H44N6O4
• 化合物HCV-IN-30U00A0,10 MM DMSO 溶液
• 化合物HCV-IN-30U00A0
• 化合物 HCV-IN-30
• (2S,2'S)-二叔丁基2,2'-(4,4'-([1,1'-双苯基]-4,4'-二基)双(1H-咪唑- 4,2-二基))双(吡咯烷-1-甲酯)
• BIS(2-甲基-2-丙基)(2S,2'S)-2,2'-[4,4'-联苯二基双(1H-咪唑-4,2-二基)]二(1-吡咯烷羧酸酯)
• DK-N-2(达卡他韦中间体2)
• 达卡他韦中间体02
• (2S,2'S)-二叔丁基 2,2'-(4,4'-([1,1'-双苯基]-4,4'-二基)双(1H-咪唑- 4,2-二基))双(吡咯烷-1-甲酯)
• 达卡他韦中间体 DK N-2
• (2S,2'S)-二叔丁基 2,2'-(4,4'-([1,1'-双苯基]-4,4'-二基)双(1H-咪唑- 4,2-二基))双(吡咯烷-1-甲酯)(中间体2)
• 达卡他韦中间体II
• (2S,2'S)-2,2'-([1,1'-联苯]-4,4'-二基二-1H-咪唑-5,2-二基)二-1-吡咯烷羧酸 1,1'-二叔丁基酯
• 达卡他韦中间体1007882-23-6
• 达卡他韦中间体2
• 1007882-23-6
• (2S,2'S)-2,2'-([1,1'-Biphenyl]-4,4'-diyldi-1H-imidazole-5,2-diyl)bis-1-pyrrolidinecarboxylic acid 1,1'-bis(1,1-dimethylethyl) ester
• HCV-IN-30, 10 mM in DMSO
• 1-Pyrrolidinecarboxylic acid, 2,2'-([1,1'-biphenyl]-4,4'-diyldi-1H
• 2-(4-{4'-[2-((2S)-1-tert-butoxycarbonyl-pyrrolidin-2-yl)-1H-imidazol-4-yl]-biphenyl-4-yl}-1H-imidazol-2-yl)-(2S)-pyrrolidine-1-carboxylic acid tert-butyl ester
• Intermediate II of Dacatavir
• 1,1'-Bis(1,1-dimethylethyl) (2S,2'S)-2,2'-([1,1'-biphenyl]-4,4'-diyldi-1H-imidazole-5,2-diyl)bis[1-pyrrolidinecarboxylate
• 1-Pyrrolidinecarboxylic acid,2,2'-([1,1'-biphenyl]-4,4'-diyldi-1H-imidazole-5,2-diyl)bis-
• 1-Pyrrolidinecarboxylic acid, 2,2'-([1,1'-biphenyl]-4,4'-diy...
• (2S,2''S)-Di-tert-butyl 2,2''-(5,5''-([1,1''-biphenyl]-4,4''-diyl)bis(1h-imidazole-5,2-diyl))bis(pyrrolidine-1-carboxylate)
• HCV-IN-30
• Daclatasvir Intermediate-2
• EOS-61352
• di-tert-butyl (2S,2'S)-2,2'-(4,4'-biphenyldiylbis(1H-imidazole-5,2-diyl))di(1-pyrrolidinecarboxylate)
• (2S,2'S)-
• (2S,2'S)-di-tert-butyl 2,2'-(4,4'-([1,1'-biphenyl]-4,4'-diyl)bis(1H-iMidazole-4,2-diyl))bis(pyrrolidine-1-carboxylate)
• 1-Pyrrolidinecarboxylic acid, 2,2'-([1,1'-biphenyl]-4,4'-diyldi-1H-iMidazole-5,2-diyl)bis-, 1,1'-bis(1,1-diMethylethyl) ester, (2S,2'S)-
• 1-Pyrrolidinecarboxylic acid, 2,2'-([1,1'-biphenyl]-4,4'-diyldi-1H-iMidazole-5,2-diyl)bis-, 1,1'-bis(1,1-diMethylethyl) ester, (2S,2'S)-nyl
• Daclatasvir intermediate 02
• 2-(5-(4'-(2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-1H-imidazol-4-yl)-[1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate
• Di-tert-butyl2,2'-([1,1'-biphenyl]-4,4'-diylbis(1H-imidazole-5,2-diyl))(2S,2'S)-bis(pyridineidine-1-carboxylate)
• Di-tert-butyl2,2'-([1,1'-biphenyl]-4,4'-diylbis(1H-imidazole-5,2-diyl))(2S,2'S)-bis(pyridineidine-1-
• Bis(2-methyl-2-propanyl) (2S,2'S)-2,2'-[4,4'-biphenyldiylbis(1H-imidazole-4,2-diyl)]di(1-pyrrolidinecarboxylate)
• Daclatasvir Intermediates 4
• Methyl-N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
• di-tert-butyl2,2'-([1,1'-biphenyl]-4,4'-diylbis(1H-imidazole-5,2-diyl))(2S,2'S)-bis(pyrrolidine-1-carboxylate)
• Daclatasvir Intermediates
• Dacaltasvir Intermediate 02
• Daclatasvir Intermediates Ⅱ
• (2S,2'S)-2,2'-[(1,1'-biphenyl)-4,4'-diyldi-1H-imidazole-5,2-diyl]bis-1-pyrrolidinecarboxylic acid ,1,1'-bis(1,1-dimethylethyl) ester